Objectives: In elderly, the increase of dementia incidence and the lack of effective therapies have stimulated the search for early markers for discrimination and prevention of this pathology. In this contest we profiled the CSF protein content in old patients with cognitive impairment affected by Alzheimer’s disease (AD) and idiopathic Normal Pressure Hydrocephalus (iNPH) compared to controls. Methods: 10 CSF from AD, 10 from iNPH patients and 12 from controls were profiled by MALDI-MS for the detection of small proteins discriminating the two forms of dementia from healthy subjects. Statistics (Wilcoxon test p<0.01, PCA analysis and ROC AUC>0.800) and classification models were performed by ClinProTools Software. For the identification of putative biomarkers (peaks discriminating the different classes), an in-gel approach (SDS-PAGE separation) coupled to MALDI-MS was adopted. Results: MALDI Profiling allowed to discriminate iNPH (resulting similar to controls) from AD patients through the presence of 28 differentially changed peaks in the acquisition range of 4-34 kDa. Among them, 6 were selected (on the base of the corresponding p-values, ROCs and box-plots) and combined to build models to classify a blind set (n=50) of CSFs. SDS-PAGE coupled to MALDI-MS allowed peak identification corresponding to a protein involved in lipid transport. Conclusions: CSF MALDI profiling can be adopted to identify protein differences in various types of dementia in order to obtain a specific pattern to support clinical and biochemical diagnosis. This approach can also provide new putative biomarkers to couple to the existing molecules, whose expression is currently evaluated in clinical practice.

CSF and serum maldi frofiling for the identification of novel biomarkers in dementia patients / C. Gelfi, C. Fania, B. Arosio, M. Casati, M. Vasso, C. Gussago, E. Torretta, E. Ferri, D. Mari. ((Intervento presentato al convegno ADPD International conference on Alzheimer's and Parkinson's diseases tenutosi a Nice nel 2015.

CSF and serum maldi frofiling for the identification of novel biomarkers in dementia patients

C. Gelfi;B. Arosio;M. Casati;C. Gussago;E. Ferri;D. Mari
2015

Abstract

Objectives: In elderly, the increase of dementia incidence and the lack of effective therapies have stimulated the search for early markers for discrimination and prevention of this pathology. In this contest we profiled the CSF protein content in old patients with cognitive impairment affected by Alzheimer’s disease (AD) and idiopathic Normal Pressure Hydrocephalus (iNPH) compared to controls. Methods: 10 CSF from AD, 10 from iNPH patients and 12 from controls were profiled by MALDI-MS for the detection of small proteins discriminating the two forms of dementia from healthy subjects. Statistics (Wilcoxon test p<0.01, PCA analysis and ROC AUC>0.800) and classification models were performed by ClinProTools Software. For the identification of putative biomarkers (peaks discriminating the different classes), an in-gel approach (SDS-PAGE separation) coupled to MALDI-MS was adopted. Results: MALDI Profiling allowed to discriminate iNPH (resulting similar to controls) from AD patients through the presence of 28 differentially changed peaks in the acquisition range of 4-34 kDa. Among them, 6 were selected (on the base of the corresponding p-values, ROCs and box-plots) and combined to build models to classify a blind set (n=50) of CSFs. SDS-PAGE coupled to MALDI-MS allowed peak identification corresponding to a protein involved in lipid transport. Conclusions: CSF MALDI profiling can be adopted to identify protein differences in various types of dementia in order to obtain a specific pattern to support clinical and biochemical diagnosis. This approach can also provide new putative biomarkers to couple to the existing molecules, whose expression is currently evaluated in clinical practice.
18-mar-2015
Settore BIO/12 - Biochimica Clinica e Biologia Molecolare Clinica
CSF and serum maldi frofiling for the identification of novel biomarkers in dementia patients / C. Gelfi, C. Fania, B. Arosio, M. Casati, M. Vasso, C. Gussago, E. Torretta, E. Ferri, D. Mari. ((Intervento presentato al convegno ADPD International conference on Alzheimer's and Parkinson's diseases tenutosi a Nice nel 2015.
Conference Object
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/271846
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact